Zenas BioPharma, Inc.
$20.9
▲
5.4%
2026-04-21 10:25:01
zenasbio.com
NMS: ZBIO
Explore Zenas BioPharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.28 B
Current Price
$20.9
52W High / Low
$44.6 / $8.09
Stock P/E
—
Book Value
$4.44
Dividend Yield
—
ROCE
-65.85%
ROE
-1.36%
Face Value
—
EPS
$-8.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
167
Beta
—
Debt / Equity
0.55
Current Ratio
5.61
Quick Ratio
5.61
Forward P/E
-4.23
Price / Sales
127.47
Enterprise Value
$830.6 M
EV / EBITDA
-3.93
EV / Revenue
83.06
Rating
Strong Buy
Target Price
$42
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 2. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 3. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 4. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 5. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 6. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 7. | GH Research PLC | $21.5 | — | $1.33 B | — | -21.68% | -21.04% | $24.66 / $8.66 | $4.51 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 10 M | 5 M | — |
| Operating Profit | -71.31 M | -47.58 M | -55.16 M | -37.33 M | -55.62 M | — |
| Net Profit | -240.44 M | -51.5 M | -52.22 M | -33.57 M | -52.6 M | — |
| EPS in Rs | -3.86 | -0.83 | -0.84 | -0.54 | -0.84 | -5.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10 M | 5 M | 50 M | 0 M |
| Operating Profit | -211.38 M | -163.89 M | -27.15 M | -75.2 M |
| Net Profit | -377.74 M | -156.99 M | -37.12 M | -119.28 M |
| EPS in Rs | -6.06 | -2.52 | -0.6 | -1.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 383.64 M | 369.97 M | 68.18 M | 74.58 M |
| Total Liabilities | 141.5 M | 57.51 M | 293.9 M | 266.87 M |
| Equity | 242.14 M | 312.46 M | -225.72 M | -192.29 M |
| Current Assets | 351.17 M | 355.92 M | 59.8 M | 68.44 M |
| Current Liabilities | 62.65 M | 57.29 M | 23.26 M | 25.97 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -172.33 M | -119.67 M | -30.53 M | -65.65 M |
| Investing CF | -251.89 M | -30.55 M | -0.02 M | -2.2 M |
| Financing CF | 215.28 M | 412.96 M | 20.12 M | 59.39 M |
| Free CF | -207.35 M | -119.81 M | -30.55 M | -67.85 M |
| Capex | -35.02 M | -0.13 M | -0.02 M | -2.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 100% | -90% | — | — |
| Earnings Growth % | -140.62% | -322.87% | 68.88% | — |
| Profit Margin % | -3777.37% | -3139.76% | -74.25% | — |
| Operating Margin % | -2113.85% | -3277.76% | -54.29% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -3704.33% | -3128.44% | -54.07% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.